ONCO — Oncopeptides AB Share News
0.000.00%
Last trade - 00:00- SEK665.09m
- SEK642.65m
- SEK71.12m
Brief: Oncopeptides Q1 Sales SEK 5.1 Million
Brief: Oncopeptides, Vector Pharma Partner To Provide Pepaxti To Patients In MENA Region
Brief: Oncopeptides, Vector Pharma FZCO To Collaborate To Offer Pepaxti To Patients In Middle East And North Africa
Brief: Oncopeptides Carries Out Fully Guaranteed Rights Issue
Brief: Oncopeptides Proposes No Dividend For Fiscal Year 2023
Brief: Oncopeptides Q4 Operating Loss Narrows To SEK 81 Million
Brief: Oncopeptides Q4 Operating Profit SEK -80.98 Million
Brief: FDA Confirms Withdrawal Of Oncopeptides' Pepaxto From US Market
Brief: Oncopeptides Gets Positive Recommendation For Pepaxti By Spanish Pricing Authority
Brief: Oncopeptides Extends Market Exclusivity For Pepaxti In Europe Until 2037
Brief: Oncopeptides Updates On Type II Application Process
Brief: Oncopeptides To Present Additional Data From Ocean Study
Brief: Oncopeptides Q3 Operating Profit SEK -37.297 Million
Brief: Oncopeptides Abandons Type II Variation Process For Pepaxti
Brief: Oncopeptides Receives Positive Opinion By CHMP On Type II Variation To Extend Therapeutic Indication Of Pepaxti
Brief: Oncopeptides Q2 Operating Profit SEK -62.43 Million
Brief: Oncopeptides Appoints Henrik Bergentoft As CFO
Brief: Oncopeptides Appoints Sofia Heigis As CEO
Brief: Oncopeptides Complete First Sales Of Pepaxti In Greece